Stockscreener 앱 받기
59.60
3.45%
-2.13
전일 마감가:
$61.73
열려 있는:
$60.23
하루 거래량:
13.60M
Relative Volume:
1.03
시가총액:
$121.69B
수익:
$48.19B
순이익/손실:
$7.06B
주가수익비율:
17.23
EPS:
3.4587
순현금흐름:
$12.85B
1주 성능:
+0.29%
1개월 성능:
-4.40%
6개월 성능:
+30.33%
1년 성능:
+0.00%
1일 변동 폭
$59.10
$60.58
1주일 범위
$58.37
$62.23
52주 변동 폭
$42.52
$62.89
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.60 | 121.69B | 48.19B | 7.06B | 12.85B | 3.4587 |
LLY
Lilly Eli Co
|
935.58 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.04 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.84 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.49 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.87 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Trust Co. of Toledo NA OH Sells 55,523 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Case-By-Case Guide As Justices Eye Landmark Pharma Law - Law360
Elkins, Bristol Myers Squibb CFO, sells $1.85 million in BMY stock - Investing.com Australia
Bristol-Myers Squibb Cancer Moves And Equity Efforts Underpin Valuation Case - Yahoo Finance UK
Growth and Income Portfolio's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Company (BMY) Options Chain - Yahoo! Finance Canada
Elkins, Bristol Myers Squibb CFO, sells $1.85 million in BMY stock By Investing.com - Investing.com South Africa
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co (BMY) Shares Down 3.58% on Apr 2 - GuruFocus
Bristol Myers Squibb Cancer Pact And Equity Push Raise Valuation Questions - simplywall.st
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.58% on Apr 2: What Signal Does It Send? - TradingKey
Bristol-Myers Squibb (BMY) Announces Positive Data from the Phase 3 SCOUT-HCM Trial of Camzyos - Insider Monkey
Ritter Alpha, LP's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Tema Etfs LLC Has $6.89 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
20,914 Shares in Bristol Myers Squibb Company $BMY Acquired by J. Safra Sarasin Holding AG - MarketBeat
F&V Capital Management LLC Boosts Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Allspring Global Investments Holdings LLC Buys 67,783 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
DF Tactical Dividend Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Janux announces development candidate nomination under Bristol Myers collab - tipranks.com
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY) - MarketBeat
Piramal Pharma Completes Acquisition of Kenalog Injectable Product from Bristol-Myers Squibb - scanx.trade
Bristol Myers Squibb (BMY) Partners with Janux on New Cancer The - GuruFocus
Janux Unveils Development Candidate in Bristol Myers Squibb Partnership, Worth $35M Milestone - Contract Pharma
Janux Therapeutics receives $35M milestone from Bristol Myers Squibb - Investing.com
Janux Therapeutics receives $35M milestone from Bristol Myers Squibb By Investing.com - Investing.com India
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - Yahoo Finance Singapore
Bristol Myers Squibb Company $BMY Shares Sold by Meyer Handelman Co. - MarketBeat
Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030: Global Industry Assessment Featuring Pfizer, Merck & Co., Bristol-Myers Squibb, AstraZeneca, Novartis and More - finance.yahoo.com
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Bristol Myers Squibb Discounts Sotyktu, Zeposia, Orencia SC on Government SiteNews and Statistics - indexbox.io
Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market - MarketWatch
Bristol Myers Squibb Stock: Dividend Reliability and Pipeline Momentum Define Investor Appeal in 202 - AD HOC NEWS
Is Bristol Myers Squibb (BMY) Price Near US$60 Supported By Cash Flow And Earnings Models - simplywall.st
Kidney Cancer Drugs Market to Grow by $2 Billion During - globenewswire.com
Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry - Yahoo Finance
Ovarian Cancer Drugs Market Outlook Report 2026-2030 - GlobeNewswire
Ovarian Cancer Drugs Market Outlook Report 2026-2030 Featuring Strategic Analysis of AstraZeneca, Roche, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer and Other Key Players - Yahoo Finance
Bristol Myers Squibb launches survey on myeloma care gaps By Investing.com - Investing.com India
Mn Services Vermogensbeheer B.V. Increases Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Retirement Systems of Alabama Boosts Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb adding 3 medications on TrumpRx - Fox Business
Multiple Myeloma Market Is Going to Boom Rapidly | Bristol-Myers - openPR.com
Should You Buy Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming Dividend? - simplywall.st
Bile Duct Cancer Market to Grow by $1.07 Billion During 2026-2030: Key Trends, Investment Opportunities and Competitive Strategies Analyzed - GlobeNewswire Inc.
Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline - Yahoo Finance
Bristol-Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment - Insider Monkey
Jim Cramer on Bristol-Myers Squibb: “The stock’s recent pullbacks have represented terrific buying opportunities” - MSN
Is Bristol-Myers Squibb Company (BMY) A Good Stock To Buy Now? - Insider Monkey
Bristol Myers Squibb Stock: Strong Growth Portfolio and Dividend Yield Position BMY Shares as a Valu - AD HOC NEWS
Bristol Myers Squibb’s Camzyos shows promise in adolescent trial By Investing.com - Investing.com UK
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.81%
1.37%
자본화:
|
볼륨(24시간):